nicotine has been researched along with ly2456302 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carroll, FI; Damaj, MI; Jackson, A; Jackson, KJ | 1 |
| Babalonis, S; Comer, SD; Fraser, H; Jones, JD; Kelsh, D; Lofwall, MR; Marcus, R; Martinez, DM; Martinez, S; Nunes, EV; Paterson, B; Vince, B; Walsh, SL | 1 |
2 other study(ies) available for nicotine and ly2456302
| Article | Year |
|---|---|
Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice.
Topics: Animals; Anxiety; Benzamides; Conditioning, Psychological; Disease Models, Animal; Hot Temperature; Hyperalgesia; Male; Mice, Inbred ICR; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Pyrrolidines; Receptors, Opioid, kappa; Spatial Behavior; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2015 |
A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERC-501, in a human laboratory model of smoking behavior.
Topics: Adult; Affect; Anxiety; Benzamides; Cigarette Smoking; Craving; Cross-Over Studies; Double-Blind Method; Female; Humans; Male; Middle Aged; Narcotic Antagonists; Nicotine; Nicotinic Agonists; Pyrrolidines; Random Allocation; Receptors, Opioid, kappa; Smoking Cessation; Substance Withdrawal Syndrome; Tobacco Use Disorder | 2020 |